CN115925896A - Novel coronavirus RBD specific monoclonal antibody and application - Google Patents
Novel coronavirus RBD specific monoclonal antibody and application Download PDFInfo
- Publication number
- CN115925896A CN115925896A CN202210906254.4A CN202210906254A CN115925896A CN 115925896 A CN115925896 A CN 115925896A CN 202210906254 A CN202210906254 A CN 202210906254A CN 115925896 A CN115925896 A CN 115925896A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- monoclonal antibody
- rbd
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 26
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 15
- 241001678559 COVID-19 virus Species 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000012827 research and development Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 10
- 239000004005 microsphere Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 102100031673 Corneodesmosin Human genes 0.000 description 6
- 101710139375 Corneodesmosin Proteins 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000000137 annealing Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 238000012257 pre-denaturation Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 210000004180 plasmocyte Anatomy 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of monoclonal antibodies, and particularly discloses a novel coronavirus RBD specific monoclonal antibody and application of the novel coronavirus RBD specific monoclonal antibody. The invention has important scientific significance and application prospect for the prevention and clinical treatment of diseases caused by the novel coronavirus SARS-CoV-2 and the research and development of diagnostic reagents.
Description
Technical Field
The invention belongs to the technical field of monoclonal antibodies, and particularly relates to a novel coronavirus RBD specific monoclonal antibody and application thereof.
Background
Antibodies are immunoglobulin molecules composed of four polypeptide chains, including two heavy chains (H chains) and two light chains (L chains). The H chain consists of a heavy chain variable region (VH) and a heavy chain constant region consisting of three regions, CH1, CH2 and CH 3. The L chain consists of an L variable region (VL) and a light chain constant region consisting of a CL region. VH and VL can be further divided into hypervariable regions known as Complementarity Determining Regions (CDRs) and conserved regions known as Framework Regions (FR) that alternate.
The research shows that: the novel coronavirus (SARS-CoV-2) has four major structural proteins, the spike protein (S protein), the nucleocapsid protein (N protein), the membrane protein (M protein), and the envelope protein (E protein), respectively, wherein the S protein has two subunits: s1 and S2, receptor Binding Sites (RBDs) are located on the S1 subunit, and their primary function is to recognize host cell surface receptors, mediating fusion with host cells.
Chinese invention patent application with application publication No. CN111303280A discloses a fully human monoclonal antibody against SARS-CoV-2 with high neutralizing activity, which provides a fully human monoclonal antibody with a recognition region of S1 non-RBD region, but the blocking effect of the fully human monoclonal antibody on virus obtained by the above patent is limited because the novel coronavirus invading host cell is combined with ACE2 of the host cell through RBD, and the antibody cDNA obtained by marking plasma cell is reacted rapidly after the memory B cell is activated, compared with plasma cell, so the memory B cell can induce faster than the initial reaction and stronger humoral immune response, and the humoral immune response induced by plasma cell is limited.
Disclosure of Invention
The invention aims to provide a novel coronavirus RBD specific monoclonal antibody which is directed to RBD and can trigger stronger humoral immune response and application thereof.
In order to achieve the above objects, the present invention provides a novel coronavirus RBD-specific monoclonal antibody, specifically, the heavy chain amino acid sequence of the antibody can be shown as SEQ ID NO. 1; the light chain amino acid sequence can also be shown as SEQ ID NO:2 (monoclonal antibody 2-CQTS 002). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 3; the light chain amino acid sequence can also be shown as SEQ ID NO:4 (mAb 3-CQTS 003). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 5; the light chain amino acid sequence can also be shown as SEQ ID NO:6 (mAb 5-CQTS 005). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 7; the light chain amino acid sequence can also be shown as SEQ ID NO:8 (mAb 6-CQTS 006). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 9; the light chain amino acid sequence may also be shown as SEQ ID NO:10 (mAb 7-CQTS 007). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 11; the light chain amino acid sequence can also be shown as SEQ ID NO:12 (monoclonal antibody 8-CQTS 008). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 13; the light chain amino acid sequence can also be shown as SEQ ID NO:14 (mAb 9-CQTS 009). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 15; the light chain amino acid sequence can also be shown as SEQ ID NO:16 (monoclonal antibody 10-CQTS 010). The invention also provides the use of the above-mentioned novel coronavirus RBD-specific monoclonal antibody in the preparation of a reagent or vaccine or medicament for detecting or diagnosing SARS-CoV-2, wherein the medicament comprises the novel coronavirus RBD-specific monoclonal antibody as defined in any one of claims 1 to 8 and a pharmaceutically acceptable excipient, diluent or carrier; also provided are nucleic acid molecules encoding the novel coronavirus RBD-specific monoclonal antibodies described above; also provides an expression cassette, a recombinant vector, a recombinant bacterium or a transgenic cell line containing the nucleic acid molecule; also provides the application of the expression cassette, the recombinant vector, the recombinant bacterium or the transgenic cell line in the preparation of products.
The invention also provides a product which comprises the novel coronavirus RBD specific monoclonal antibody; the product is used in any one of the following (b 1) to (b 4): (b 1) binds to novel coronavirus SARS-CoV-2; (b 2) detecting binding of the novel coronavirus SARS-CoV-2; (b 3) binding to the S protein of the novel coronavirus SARS-CoV-2; (b 4) detecting the S protein of the novel coronavirus SARS-CoV-2.
Preferably, the novel coronavirus RBD-specific monoclonal antibody is obtained by sorting RBD-specific memory B cells and obtaining antibody variable region cDNA from mRNA of the RBD-specific memory B cells.
The principle and the beneficial effects of the invention are as follows:
(1) The monoclonal antibody provided by the invention has RBD specificity, and compared with a monoclonal antibody aiming at an S1 non-RBD region, the monoclonal antibody provided by the invention is combined with RBD, thereby providing wider application value for screening antibody drugs, diagnosing, preventing and treating novel coronavirus pneumonia.
(2) The monoclonal antibody provided by the invention is obtained by sorting RBD specific memory B cells, and compared with the prior art of sorting plasma cells, the monoclonal antibody prepared by the invention can trigger stronger humoral immune response. In addition, the invention only aims at RBD specific memory B cells to carry out subsequent RT-PCR, nested PCR and antibody function analysis, thereby greatly improving the specific binding capacity of the monoclonal antibody and the RBD.
Drawings
FIG. 1 is a cytometric map of memory B cells analyzed using flow cytometry;
FIG. 2 is a cell sorting graph of RBD specific memory B cells analyzed by flow cytometry;
FIG. 3 is a gel electrophoresis of the PCR product of the antibody gene of a single cell;
FIG. 4 is a photograph of agarose gel electrophoresis following PCR amplification of an antibody gene expression cassette containing the CMV promoter, WPRE-gamma or WPRE-kappa element;
FIG. 5 is a graph showing the results of an experiment on the specificity of RBD.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
This example provides a novel coronavirus RBD specific monoclonal antibody, whose heavy chain amino acid sequence is shown in SEQ ID NO. 1; the light chain amino acid sequence is shown as SEQ ID NO. 2.
The embodiment also provides the application of the novel coronavirus RBD specific monoclonal antibody in the preparation of a reagent or a medicament for detecting or diagnosing SARS-CoV-2.
In practical production, the RBD-specific monoclonal antibody obtained in this example can be used to prepare a nucleic acid molecule, or an expression cassette, a recombinant vector, a recombinant bacterium or a transgenic cell line containing the nucleic acid molecule, or a pharmaceutical composition comprising the novel coronavirus RBD-specific monoclonal antibody and a pharmaceutically acceptable excipient, diluent or carrier.
In application, the related product prepared by the RBD specific monoclonal antibody obtained in the embodiment can have the following application of any one of (b 1) to (b 4): (b 1) binds to novel coronavirus SARS-CoV-2; (b 2) detecting binding of the novel coronavirus SARS-CoV-2; (b 3) binding to the S protein of the novel coronavirus SARS-CoV-2; (b 4) detecting the S protein of the novel coronavirus SARS-CoV-2.
Examples 2 to 8
Examples 2-8 differ from example 1 in that: the amino acid sequences of the RBD-specific monoclonal antibodies were varied, and the amino acid sequences of examples 2-8 are shown in the following table:
experimental group | Heavy chain amino acid sequence | Light chain amino acid sequence |
Example 1 CQTS002 | SEQ ID NO:1 | SEQ ID NO:2 |
Example 2 CQTS003 | SEQ ID NO:3 | SEQ ID NO:4 |
Example 3 CQTS005 | SEQ ID NO:5 | SEQ ID NO:6 |
Example 4 CQTS006 | SEQ ID NO:7 | SEQ ID NO:8 |
Example 5 CQTS007 | SEQ ID NO:9 | SEQ ID NO:10 |
Example 6 CQTS008 | SEQ ID NO:11 | SEQ ID NO:12 |
Example 7 CQTS009 | SEQ ID NO:13 | SEQ ID NO:14 |
Example 8 CQTS010 | SEQ ID NO:15 | SEQ ID NO:16 |
The RBD-specific monoclonal antibodies provided in examples 1-8 above were obtained by the following method: firstly, single RBD specific memory B cells are obtained by separating peripheral blood of a rehabilitation patient with the novel coronavirus pneumonia, then mRNA of the RBD specific memory B cells is obtained, then an antibody variable region gene expression box is constructed by RT-PCR and nested PCR, then the antibody variable region gene expression box is transduced into 293T cells to express an antibody, supernatant is collected, the RBD specificity of the supernatant is detected by an ELISA method, and RBD specific monoclonal antibodies are obtained by screening.
The method specifically comprises the following steps:
s1, collecting peripheral blood of a plurality of novel coronavirus pneumonia rehabilitation patients, separating to obtain PBMC, and freezing and storing in a refrigerator at-80 ℃ for later use.
S2, firstly removing Dead cells of PBMC obtained in the S1 by adopting Dead cell removing Dye (Dead Dye), then adopting CD19, mIg-G, mIg-D and S-RBD to Dye and mark live RBD in the PBMC with high specificity and high binding capacity for memory B cells, and screening memory B cells specific to the RBD; specific memory B cells were sorted using a flow cytometric sorter onto 96-well plates, one specific memory B cell per well, and frozen at-80 ℃ in a freezer for use.
Specifically, the preferred concentration range of the Dead Dye staining in this embodiment is 1-2 μ g/mL, and the preferred concentration range of the Dead Dye staining in this embodiment is 1.5 μ g/mL; CD19 is a B cell marker produced by Biolegend and is stained at a concentration in the range of 1-2. Mu.g/mL, and in this example, CD19 is preferably stained at a concentration of 1.5. Mu.g/mL. mIg-G is a B cell surface receptor produced by Biolegend, and the concentration range of the mIg-G during staining is 1-2 mu G/mL, and the concentration of the mIg-G during staining is 1.5 mu G/mL in the embodiment; mIg-D is B cell surface receptor produced by Biolegend, and the concentration range when staining is 1-2 μ g/mL, and the concentration when staining mIg-D is 1.5 μ g/mL is preferred in the embodiment; S-RBD is a novel coronavirus produced by sinobiological, protein receptor domain, and the concentration range when staining is 1-2. Mu.g/mL, and the concentration when staining S-RBD is 1.5. Mu.g/mL is preferred in this example.
Cell sorting of PBMC by CD19, mIg-G, mIg-D and S-RBD for RBD-specific memory B cell sorting by flow cytometry the cell sorting profiles for B cells with memory specific to S-RBD are shown in FIGS. 1 and 2, where Batch ID 0428, 0505, 0522, 0528 in FIG. 2 are screening batches. The principle of screening RBD-specific memory B cells by using CD19, mIg-G, mIg-D and S-RBD in this example is as follows: PBMC were stained with Dead cell stain (Dead Dye), B cell marker CD19, memory B cell markers mIg-G positive and mIg-D negative, and memory B cells expressing RBD-specific IgG, then the CD19 cell population was divided from the cell population using a flow cytometer, and mIg-G was divided from the CD19 positive cell population + mIg-D - Cell population from mIg-G + mIg-D - Dividing the cell group into RBD positive memory B cells, and sorting the RBD positive memory B cells by a flow cytometric sorter.
S3, sorting to obtain mRNA of a single RBD specific memory B cell, and performing RT-PCR amplification to obtain antibody variable region cDNA. Specifically, when RT-PCR is used to amplify cDNA in the variable region of the antibody, the primer front segment of the primer designed in this example is designed with a universal Leader (see primer sequence listing one and primer sequence listing two), which effectively improves the amplification rate of the antibody gene, and the experimental result is shown in fig. 3.
S4, amplifying the cDNA of the antibody variable region obtained from the S1-S3 by adopting nested PCR to construct an antibody variable region gene expression cassette.
S3 and S4 are performed by the following six sections in total: (1) extracting mRNA of RBD specific memory B cells; (2) single cell mRNA Reverse Transcription (RT); (3) adding G tail (TDT); (4) first round PCR (1 st PCR); (5) second round PCR (2 ndPCR); (6) BCR-ORF PCR amplification construction gene expression cassette; (7) CMV, WPRE-gamma/kappa/l fragment amplification and CMV, BCR-V gamma/kappa/l ((6) product), WPRE-gamma/kappa/l Overlap PCR (Overlap PCR) pre-connection; (8) BCR-gamma ORF, BCR-kappa ORF and BCR-lPCR amplification.
The preparation and reaction conditions of each part of reaction liquid are as follows:
(1) Using Dynabeads TM mRNA DIRECT TM The single cell mRNA extraction is carried out by a Purification Kit (Thermo Fisherscientific), and the method specifically comprises the following steps:
(1) centrifuging: taking out the 96-well plate with the single RBD specific memory B cell from a refrigerator at the temperature of-80 ℃, and centrifuging the plate at the speed of 600 Xg for 30s to ensure that the cell is centrifuged at the bottom of the well;
(2) cleaning: taking out a Dynabeads oligo (dT) 25 microsphere bottle, uniformly mixing by vortex, sucking enough microspheres according to 2 mu l/hole, placing on a magnet block, standing for 30s, discarding supernatant, and resuspending by using 500 mu l lysine Buffer;
(3) preparation: adding the microspheres into a 50mL centrifuge tube according to 9. Mu.l/hole lysine Buffer, adding the 500. Mu.l microsphere suspension, and uniformly blowing by using a gun;
(4) subpackaging: subpackaging the microspheres by using an eight-connecting tube, and then adding the microspheres into a cell plate according to 9 mu l/hole by using a discharge gun;
(5) rinsing: pasting a film on a 96-hole plate, then rinsing the periphery of the tube wall for 2 cycles;
(6) and (3) incubation: standing at room temperature for 5min to fully release mRNA of RBD specific memory B cells and combine the mRNA to the microspheres, and after the incubation is finished, performing 600 Xg instantaneous centrifugation to enable the microspheres to be centrifuged at the bottom of the hole. Place 96-well plates in DynaMag TM -96side Magnet magnetic plate, pipette off supernatant;
(7) wash A: adding Washing Buffer A according to 8 mul/hole, walking the plate back and forth for 7-8 times to fully wash the microspheres, and discarding the supernatant;
(8) wash B: wash Buffer B was added at 8. Mu.l/well, the plate was walked back and forth 7-8 times to wash the microspheres thoroughly, the supernatant was discarded, and then the pre-prepared Reverse Transcription (RT) reaction was added at 10. Mu.l/well. The reagent preparation and reaction conditions are described in the following (2).
(2) Reverse Transcription (RT) (10 μ l system): the reagents required for formulation are shown in table 1 below.
Name of reagent | Volume of |
DEPC-H 2 O | 4.5μl |
5×primerscript Buffer | 2.0μl |
2.5mM dNTP | 2.0μl |
RNase Inhibitor | 1μl |
Sample | beads |
PrimerScript ⅡRTase | 0.5μl |
Total volume | 10μl |
Reaction conditions are as follows: 42 ℃ for 60min (mix every 20 min).
After the reaction was completed, the 96-well plate was instantaneously centrifuged at 600 Xg, and then the 96-well plate was placed on DynaMag TM On a 96-side Magnet magnetic plate, the supernatant was aspirated off by a discharge gun, and then a previously prepared TDT reaction solution was added at 10. Mu.l/well, and the reagent preparation and reaction conditions were as described in (3) below.
(3) Add G tail (TDT) (10. Mu.l system): the reagents required for formulation are shown in table 2 below.
Name of reagent | Volume of |
H 2 O | 6.4μl |
5×TdT buffer | 2.0μl |
10mM dGTP | 0.5μl |
0.1%BSA | 1.0μl |
Sample | beads |
TdT | 0.1μl |
Total volume | 10μl |
The reaction conditions are as follows: 37 ℃ for 40min (every 20min mixing).
After the reaction, the reaction mixture was centrifuged at 600 Xg in a 96-well plate and then placed in DynaMag TM On a 96-side Magnet magnetic plate, the supernatant was aspirated off by a pipette, and then 10. Mu.l/well of a first PCR (1 st PCR) reaction solution prepared in advance was added thereto, and the reagents were prepared under the following conditionsThe description of (4) above.
(4) 1st PCR (10. Mu.l system) (see primer sequence Listing): the reagents required for formulation are shown in table 3 below:
name of reagent | Volume of |
H 2 O | 1.9μl |
2×GC Buffer | 5μl |
2.5mM dNTP | 1μl |
FP:AP3-dC(10μM) | 0.5μl |
RP1:Cg-1st(10μM) | 0.5μl |
RP2:Ck-1st(10μM) | 0.5μl |
RP3:CI-RT(10μM) | 0.5μl |
PrimesTAR | 0.1μl |
sample | beads |
Total volume | 10μl |
Based on the PCR principle, the experimental reaction conditions of 1st PCR are as follows: (1) pre-denaturation at 95 ℃ for 3min; (2) denaturation at 95 ℃ for 15sec, annealing at 60 ℃ for 5sec, elongation at 72 ℃ for 1min,30-35cycles, preferably 30cycles in this example; (3) extension is carried out for 5min at 72 ℃ in a circulating way, and the product is stored at 4 ℃.
(5) Second round PCR (2 nd PCR) (10. Mu.l system) (see primer sequence Listing one and primer sequence Listing two): the reagents required for formulation are shown in table 4 below:
name of reagent | Volume of |
H 2 O | 1.5μl |
2×GC Buffer | 5μl |
2.5mM dNTP | 1μl |
FP:MAC-AP3/AP3(10μM) | 0.5μl |
RP:Cg-nest/K20/CI-nest(10μM) | 0.5μl |
PrimesTAR | 0.5μl |
sample | 1μl |
Total volume | 10μl |
Based on the PCR principle, the experimental reaction conditions of 2nd PCR are as follows: (1) pre-denaturation at 95 ℃ for 3min; (2) denaturation at 95 ℃ for 15sec, annealing at 60 ℃ for 5s, elongation at 72 ℃ for 1min,30-35cycles, preferably 35cycles in this example; extension is carried out for 5min at 72 ℃ in a circulating way, and the product is stored at 4 ℃.
After the PCR is finished: mu.l of each well was subjected to 1.5% agarose gel electrophoresis. The cell pore paired with the Gamma chain and Kappa chain or Lamada chain was sequenced.
(6) Amplification and construction of antibody expression cassette (BCR-ORF): PCR amplification promoter region (CMV promoter), WPRE-gamma (antibody gamma chain) and WPRE-kappa (antibody kappa chain) the PCR amplification system is shown in Table 5 below.
The PCR amplification conditions were: (1) pre-denaturation at 95 ℃ for 3min; (2) denaturation at 95 ℃ for 15sec, annealing at 56 ℃ for 15sec, elongation at 72 ℃ for 1min,30cycles; (3) circulating at 72 deg.C for external extension of 5min, and storing at 12 deg.C.
(7) CMV, WPRE-gamma/kappa/l fragment amplification and CMV, BCR-Vgamma/kappa/l, WPRE-gamma/kappa/l Overlap PCR (Overlap PCR) pre-connection, the experimental system is shown in the following table 6.
The PCR amplification conditions were: pre-denaturation at 95 ℃ for 3min; denaturation at 95 ℃ for 15sec, annealing at 50 ℃ for 15sec, elongation at 72 ℃ for 1.5min,10cycles; extension is carried out for 5min at 72 ℃ in a circulating way, and the product is stored at 12 ℃.
(8) BCR-gamma ORF, BCR-kappa ORF and BCR-l PCR amplification: the experimental system is shown in table 7 below.
PCR amplification procedure: pre-denaturation at 95 ℃ for 3min; denaturation at 95 ℃ for 15sec, annealing at 58 ℃ for 15sec, elongation at 72 ℃ for 1.5min,30cycles; circulating at 72 deg.C for external extension of 5min, and storing at 12 deg.C.
After amplification, agarose gel electrophoresis is adopted, and whether the size of the obtained antibody variable region gene is correct or not is analyzed by gel imaging, the experimental result is shown in figure 4, the Marker is in the middle position, and the strip is in the position of 5000 bp.
BCR-gamma ORF and BCR-kappa/ORF ethanol precipitation: respectively placing 30 mul of PCR products of BCR-gamma ORF and BCR-kappa ORF into an 8-connection tube, adding 120 mul of absolute ethyl alcohol and 6 mul of sodium acetate solution, fully and uniformly mixing, and standing for 30min at-80 ℃;10000rpm, centrifuging for 20min, discarding the supernatant, sequentially rinsing with 200 μ l of 70% ethanol and anhydrous ethanol once respectively, fully volatilizing the ethanol at 56 deg.C, adding 40 μ l of sterile water, oscillating to fully dissolve the precipitate, and detecting the concentration of antibody variable region gene.
The Leader primers used in S3 and S4 are described in the following primer sequence I:
the J-region primers used for S3 and S4 are described in the following primer sequence Listing:
and S5, transducing the antibody variable region gene expression cassette obtained in the S4 into 293T cells for 48 hours to express the antibody, collecting the supernatant, detecting the RBD specificity of the supernatant by using an ELISA method, and screening the RBD specific fully human monoclonal antibody.
(A) Antigen was diluted with PBS (final concentration 2. Mu.g/mL), 10. Mu.l/well, and coated onto 384-well ELISA plates overnight at 4 ℃ or 2h at 37 ℃ (4 ℃ overnight is preferred in this example). NOTE: after the addition, the liquid is instantly centrifuged to ensure that the liquid is at the bottom.
The experimental system is shown in table 8 below:
name of reagent | Goods number | Original concentration | Final concentration | Dilution ratio |
SARS-COV-2RBD | Cat:40592-V08H | 200μg/mL | 2μg/mL | 1:100 |
GoatpabtoHuIgG-ALP | Cat:ab97221 | 1mg/mL | 2μg/mL | 1:500 |
(B) PBST (0.05% Tween 20, cat #, TB220) was prepared: 1L of PBS was added with 0.5mL of Tween 20;
PBST machine washed plates (Thermoscientific wellwash versa) or hand washed (plates that were machine washed were still manually clapped/centrifuged using a microplate centrifuge (MPC-P25) for 1min to make the plates invisible to water and air bubbles).
And (3) sealing: 80 μ l of BSA (BioFroxx, cat. NO:4240GR 100) at 5% (prepared in PBST) was added to the washed plate and incubated at 37 ℃ for 1 hour in an incubator. PBST machine washing board or hand washing.
(C) Sample adding and standard substance. Wherein, the standard substance: 10 μ l/well stock concentration 1 μ g/mL, gradient dilutions 250ng/mL, 125ng/mL, 62.5ng/mL, 31.25ng/mL, 15.63ng/mL, 7.81ng/mL, 3.9ng/mL, and 1.95ng/mL. (dilution of blocking solution); sample preparation: cell supernatants transfected with antibody genes. Negative control/blank wells: blocking solution 10. Mu.l/well.
Incubate at 37 ℃ for 30min. PBST machine washing board or hand washing.
(D) Secondary antibody was added at a concentration of 10. Mu.l/well, followed by incubation at 37 ℃ for 30min.
The experimental system is shown in table 9 below:
PBST machine washing board or hand washing. Mu.l/well of PNPP (disodium p-nitrophenylphosphate) and OD (450 mm) values of 5min,10 min, 15min, 20min, 25min, 30min, 35min, 40min, 45min, 50min, 55min and 60min were measured using (Thermoscientific Muttiskan GO). 50mg PNPP powder (Thermo, prod # 34045) +40mL ddH 2 O +10mL of Diethylhanol amine substrate Buffer (5X), and PNPP was stored at 4 ℃ protected from light.
The results are shown in FIG. 5, and FIG. 5 shows that the OD value greater than 0.1 is positive.
The foregoing is merely a preferred embodiment of this invention, which is intended to be illustrative, not limiting; it will be appreciated by those skilled in the art that many changes, modifications and equivalents can be made thereto within the spirit and scope of the invention as defined by the appended claims and all such modifications and equivalents fall within the scope of the invention.
Claims (10)
1. The novel coronavirus RBD specific monoclonal antibody is characterized in that the heavy chain amino acid sequence is shown as SEQ ID NO. 1; the light chain amino acid sequence is shown as SEQ ID NO. 2.
2. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further represented by SEQ ID No. 3; the light chain amino acid sequence can also be shown as SEQ ID NO. 4.
3. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further represented by SEQ ID No. 5; the light chain amino acid sequence can also be shown as SEQ ID NO 6.
4. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further represented by SEQ ID No. 7; the light chain amino acid sequence can also be shown as SEQ ID NO. 8.
5. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further represented by SEQ ID No. 9; the light chain amino acid sequence can also be shown as SEQ ID NO. 10.
6. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further represented by SEQ ID No. 11; the light chain amino acid sequence can also be shown as SEQ ID NO 12.
7. The novel coronavirus RBD-specific monoclonal antibody of claim 1 wherein the heavy chain amino acid sequence is further defined as SEQ ID No. 13; the light chain amino acid sequence can also be shown as SEQ ID NO. 14.
8. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further as set forth in SEQ ID No. 15; the light chain amino acid sequence can also be shown as SEQ ID NO 16.
9. The novel coronavirus RBD specific monoclonal antibody according to any one of claims 1-8, wherein the antibody variable region cDNA is obtained from the mRNA of an RBD specific memory B cell by sorting the RBD specific memory B cell.
10. Nucleic acid molecule encoding a novel coronavirus RBD specific monoclonal antibody according to any one of claims 1-8.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210906254.4A CN115925896A (en) | 2020-08-19 | 2020-08-19 | Novel coronavirus RBD specific monoclonal antibody and application |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210906254.4A CN115925896A (en) | 2020-08-19 | 2020-08-19 | Novel coronavirus RBD specific monoclonal antibody and application |
CN202010839864.8A CN111909263B (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010839864.8A Division CN111909263B (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115925896A true CN115925896A (en) | 2023-04-07 |
Family
ID=73279100
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311018625.6A Pending CN117003862A (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
CN202210564961.XA Active CN114920832B (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
CN202311018647.2A Pending CN117736313A (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
CN202010839864.8A Active CN111909263B (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
CN202210906254.4A Pending CN115925896A (en) | 2020-08-19 | 2020-08-19 | Novel coronavirus RBD specific monoclonal antibody and application |
CN202311018641.5A Pending CN118085068A (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
CN202311018623.7A Active CN116813760B (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311018625.6A Pending CN117003862A (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
CN202210564961.XA Active CN114920832B (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
CN202311018647.2A Pending CN117736313A (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
CN202010839864.8A Active CN111909263B (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311018641.5A Pending CN118085068A (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
CN202311018623.7A Active CN116813760B (en) | 2020-08-19 | 2020-08-19 | New coronavirus RBD specific monoclonal antibody and application |
Country Status (2)
Country | Link |
---|---|
CN (7) | CN117003862A (en) |
WO (1) | WO2022037616A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7116256B1 (en) | 2020-04-02 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Anti-SARS-COV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments |
CR20220660A (en) | 2020-06-03 | 2023-02-17 | Regeneron Pharma | METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES |
CN117003862A (en) * | 2020-08-19 | 2023-11-07 | 重庆医科大学 | New coronavirus RBD specific monoclonal antibody and application |
CN115340602A (en) * | 2020-08-19 | 2022-11-15 | 重庆医科大学 | New coronavirus RBD specific monoclonal antibody and application |
WO2022102744A1 (en) * | 2020-11-13 | 2022-05-19 | 株式会社ハカレル | Antibody against spike protein of sars-cov-2 |
WO2022112392A1 (en) * | 2020-11-26 | 2022-06-02 | Memo Therapeutics Ag | Anti-sars-cov-2 antibody molecules |
WO2022179561A1 (en) * | 2021-02-24 | 2022-09-01 | The University Of Hong Kong | Neutralizing antibodies against covid-19 and methods of use thereof |
CN113388031B (en) * | 2021-08-17 | 2021-11-09 | 上海浙江大学高等研究院 | Monoclonal antibody 35B5, and preparation method and application thereof |
CN113388030B (en) * | 2021-08-17 | 2021-11-23 | 上海浙江大学高等研究院 | Monoclonal antibody 32C7, and preparation method and application thereof |
TW202337497A (en) | 2022-02-18 | 2023-10-01 | 中國大陸商重慶明道浩悅生物科技有限公司 | Intranasal formulations and anti-sars-cov-2-spike protein antibodies |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111187354B (en) * | 2020-02-20 | 2020-11-27 | 北京新创生物工程有限公司 | Novel coronavirus (SARS-CoV-2) IgM/IgG antibody detection kit |
CN111153991A (en) * | 2020-02-26 | 2020-05-15 | 北京博奥森生物技术有限公司 | Human SARS-CoV-2 monoclonal antibody and its preparation method and use |
GB202003632D0 (en) * | 2020-03-12 | 2020-04-29 | Harbour Antibodies Bv | SARS-Cov-2 (SARS2, COVID-19) antibodies |
CN111303279B (en) * | 2020-03-17 | 2022-02-15 | 北京凯因科技股份有限公司 | Single-domain antibody for novel coronavirus and application thereof |
CN111303280B (en) * | 2020-03-22 | 2022-01-07 | 中国人民解放军军事科学院军事医学研究院 | High-neutralization-activity anti-SARS-CoV-2 fully human monoclonal antibody and application |
CN111856027B (en) * | 2020-04-16 | 2022-05-10 | 中国科学院苏州纳米技术与纳米仿生研究所 | New coronavirus antibody detection kit suitable for examination of patients without obvious symptoms |
CN111505285A (en) * | 2020-04-27 | 2020-08-07 | 东莞博识生物科技有限公司 | SARS-CoV-2 detecting chip and its application |
CN111995675B (en) * | 2020-05-15 | 2021-03-23 | 潍坊医学院 | Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof |
RU2723008C9 (en) * | 2020-05-19 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Method for producing chinese hamster ovary cell strain, producer of sars-cov-2 virus recombinant rbd protein, chinese hamster ovary cell strain, producer of recombinant rbd protein of sars-cov-2 virus, method of producing recombinant rbd protein of sars-cov-2 virus, a test system for enzyme-linked immunosorbent assay of human blood serum or plasma and its use |
CN117003862A (en) * | 2020-08-19 | 2023-11-07 | 重庆医科大学 | New coronavirus RBD specific monoclonal antibody and application |
-
2020
- 2020-08-19 CN CN202311018625.6A patent/CN117003862A/en active Pending
- 2020-08-19 CN CN202210564961.XA patent/CN114920832B/en active Active
- 2020-08-19 CN CN202311018647.2A patent/CN117736313A/en active Pending
- 2020-08-19 CN CN202010839864.8A patent/CN111909263B/en active Active
- 2020-08-19 CN CN202210906254.4A patent/CN115925896A/en active Pending
- 2020-08-19 CN CN202311018641.5A patent/CN118085068A/en active Pending
- 2020-08-19 CN CN202311018623.7A patent/CN116813760B/en active Active
-
2021
- 2021-08-18 WO PCT/CN2021/113261 patent/WO2022037616A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN114920832B (en) | 2023-10-13 |
WO2022037616A1 (en) | 2022-02-24 |
CN116813760B (en) | 2024-06-25 |
CN117003862A (en) | 2023-11-07 |
CN111909263B (en) | 2022-10-11 |
CN117736313A (en) | 2024-03-22 |
CN111909263A (en) | 2020-11-10 |
CN116813760A (en) | 2023-09-29 |
CN118085068A (en) | 2024-05-28 |
CN114920832A (en) | 2022-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111909260B (en) | New coronavirus RBD specific monoclonal antibody and application | |
CN111909263B (en) | New coronavirus RBD specific monoclonal antibody and application | |
CN111909261B (en) | New coronavirus RBD specific monoclonal antibody and application | |
CN111925444B (en) | New coronavirus RBD specific monoclonal antibody and application | |
CN111925440B (en) | New coronavirus RBD specific monoclonal antibody and application | |
CN111925442B (en) | New coronavirus RBD specific monoclonal antibody and application | |
CN111925441B (en) | New coronavirus RBD specific monoclonal antibody and application | |
CN111925443B (en) | New coronavirus RBD specific monoclonal antibody and application | |
CN111909262B (en) | New coronavirus RBD specific monoclonal antibody and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |